The Multiple Myeloma Channel on VJHemOnc is an independent medical education platform, supported with funding from BMS (Gold) and Legend Biotech (Bronze). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
ASH 2022 | Highlights at ASH 2022: the promise of T-cell redirecting therapies in multiple myeloma
In this video, Alexander Lesokhin, MD, Memorial Sloan-Kettering Cancer Center, New York, NY, expresses his excitement over the abundance of new data on both bispecific antibodies and CAR-T therapy presented at the 2022 ASH Annual Meeting, and highlights the value of these novel agents in the myeloma treatment landscape. This interview took place at the 64th ASH Annual Meeting and Exposition congress held in New Orleans, LA.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
